These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Tailoring functional nanostructured lipid carriers for glioblastoma treatment with enhanced permeability through in-vitro 3D BBB/BBTB models. Zwain T; Alder JE; Sabagh B; Shaw A; Burrow AJ; Singh KK Mater Sci Eng C Mater Biol Appl; 2021 Feb; 121():111774. PubMed ID: 33579439 [TBL] [Abstract][Full Text] [Related]
3. RIPL peptide-conjugated nanostructured lipid carriers for enhanced intracellular drug delivery to hepsin-expressing cancer cells. Lee SG; Kim CH; Sung SW; Lee ES; Goh MS; Yoon HY; Kang MJ; Lee S; Choi YW Int J Nanomedicine; 2018; 13():3263-3278. PubMed ID: 29910614 [TBL] [Abstract][Full Text] [Related]
4. Enhanced docetaxel delivery using sterically stabilized RIPL peptide-conjugated nanostructured lipid carriers: In vitro and in vivo antitumor efficacy against SKOV3 ovarian cancer cells. Kim CH; Kang TH; Kim BD; Lee TH; Yoon HY; Goo YT; Choi YS; Kang MJ; Choi YW Int J Pharm; 2020 Jun; 583():119393. PubMed ID: 32376445 [TBL] [Abstract][Full Text] [Related]
5. Enhanced BBB and BBTB penetration and improved anti-glioma behavior of Bortezomib through dual-targeting nanostructured lipid carriers. Farshbaf M; Mojarad-Jabali S; Hemmati S; Khosroushahi AY; Motasadizadeh H; Zarebkohan A; Valizadeh H J Control Release; 2022 May; 345():371-384. PubMed ID: 35301054 [TBL] [Abstract][Full Text] [Related]
6. Docetaxel-loaded nanostructured lipid carriers functionalized with trastuzumab (Herceptin) for HER2-positive breast cancer cells. Varshosaz J; Davoudi MA; Rasoul-Amini S J Liposome Res; 2018 Dec; 28(4):285-295. PubMed ID: 28826287 [TBL] [Abstract][Full Text] [Related]
7. Overcoming brain barriers through surface-functionalized liposomes for glioblastoma therapy; current status, challenges and future perspective. Dong C; Yu X; Jin K; Qian J Nanomedicine (Lond); 2023 Dec; 18(30):2161-2184. PubMed ID: 38180008 [TBL] [Abstract][Full Text] [Related]
8. Glioblastoma multiforme targeted delivery of docetaxel using bevacizumab-modified nanostructured lipid carriers impair in vitro cell growth and in vivo tumor progression. Di Filippo LD; Lobato Duarte J; Hofstätter Azambuja J; Isler Mancuso R; Tavares Luiz M; Hugo Sousa Araújo V; Delbone Figueiredo I; Barretto-de-Souza L; Miguel Sábio R; Sasso-Cerri E; Martins Baviera A; Crestani CC; Teresinha Ollala Saad S; Chorilli M Int J Pharm; 2022 Apr; 618():121682. PubMed ID: 35307470 [TBL] [Abstract][Full Text] [Related]
9. Nanostructured lipid carriers, solid lipid nanoparticles, and polymeric nanoparticles: which kind of drug delivery system is better for glioblastoma chemotherapy? Qu J; Zhang L; Chen Z; Mao G; Gao Z; Lai X; Zhu X; Zhu J Drug Deliv; 2016 Nov; 23(9):3408-3416. PubMed ID: 27181462 [TBL] [Abstract][Full Text] [Related]
10. Docetaxel-nicotinamide complex-loaded nanostructured lipid carriers for transdermal delivery. Fan X; Chen J; Shen Q Int J Pharm; 2013 Dec; 458(2):296-304. PubMed ID: 24177313 [TBL] [Abstract][Full Text] [Related]
11. Lipid-Based Nanocarriers in the Treatment of Glioblastoma Multiforme (GBM): Challenges and Opportunities. Gupta T; Sahoo RK; Singh H; Katke S; Chaurasiya A; Gupta U AAPS PharmSciTech; 2023 Apr; 24(4):102. PubMed ID: 37041350 [TBL] [Abstract][Full Text] [Related]
12. Docetaxel-loaded folate-modified TPGS-transfersomes for glioblastoma multiforme treatment. Luiz MT; Viegas JSR; Abriata JP; Tofani LB; Vaidergorn MM; Emery FDS; Chorilli M; Marchetti JM Mater Sci Eng C Mater Biol Appl; 2021 May; 124():112033. PubMed ID: 33947535 [TBL] [Abstract][Full Text] [Related]
13. Cysteine-Functionalized Nanostructured Lipid Carriers for Oral Delivery of Docetaxel: A Permeability and Pharmacokinetic Study. Fang G; Tang B; Chao Y; Xu H; Gou J; Zhang Y; Xu H; Tang X Mol Pharm; 2015 Jul; 12(7):2384-95. PubMed ID: 25974386 [TBL] [Abstract][Full Text] [Related]
14. Preparation and characterization of dutasteride-loaded nanostructured lipid carriers coated with stearic acid-chitosan oligomer for topical delivery. Noor NM; Sheikh K; Somavarapu S; Taylor KMG Eur J Pharm Biopharm; 2017 Aug; 117():372-384. PubMed ID: 28412472 [TBL] [Abstract][Full Text] [Related]
16. Dual effect of TAT functionalized DHAH lipid nanoparticles with neurotrophic factors in human BBB and microglia cultures. Hernando S; Nikolakopoulou P; Voulgaris D; Hernandez RM; Igartua M; Herland A Fluids Barriers CNS; 2022 Mar; 19(1):22. PubMed ID: 35300705 [TBL] [Abstract][Full Text] [Related]
17. Exploring the Promising Potential of High Permeation Vesicle-Mediated Localized Transdermal Delivery of Docetaxel in Breast Cancer To Overcome the Limitations of Systemic Chemotherapy. Bathara M; Date T; Chaudhari D; Ghadi R; Kuche K; Jain S Mol Pharm; 2020 Jul; 17(7):2473-2486. PubMed ID: 32496783 [TBL] [Abstract][Full Text] [Related]
18. A comprehensive review in improving delivery of small-molecule chemotherapeutic agents overcoming the blood-brain/brain tumor barriers for glioblastoma treatment. Wang D; Wang C; Wang L; Chen Y Drug Deliv; 2019 Dec; 26(1):551-565. PubMed ID: 31928355 [TBL] [Abstract][Full Text] [Related]
19. Novel decorated nanostructured lipid carrier for simultaneous active targeting of three anti-cancer agents. Mahoutforoush A; Solouk A; Hamishehkar H; Haghbin Nazarpak M; Abbaspour-Ravasjani S Life Sci; 2021 Aug; 279():119576. PubMed ID: 33965376 [TBL] [Abstract][Full Text] [Related]
20. An industrially viable technique for fabrication of docetaxel NLCs for oncotherapy. Kharkar PB; Talkar SS; Patravale VB Int J Pharm; 2020 Mar; 577():119082. PubMed ID: 31988031 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]